Document Detail

Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.
MedLine Citation:
PMID:  19222477     Owner:  NLM     Status:  MEDLINE    
The diagnosis of disseminated intravascular coagulation (DIC) should encompass both clinical and laboratory information. The International Society for Thrombosis and Haemostasis (ISTH) DIC scoring system provides objective measurement of DIC. Where DIC is present the scoring system correlates with key clinical observations and outcomes. It is important to repeat the tests to monitor the dynamically changing scenario based on laboratory results and clinical observations. The cornerstone of the treatment of DIC is treatment of the underlying condition. Transfusion of platelets or plasma (components) in patients with DIC should not primarily be based on laboratory results and should in general be reserved for patients who present with bleeding. In patients with DIC and bleeding or at high risk of bleeding (e.g. postoperative patients or patients due to undergo an invasive procedure) and a platelet count of <50 x 10(9)/l transfusion of platelets should be considered. In non-bleeding patients with DIC, prophylactic platelet transfusion is not given unless it is perceived that there is a high risk of bleeding. In bleeding patients with DIC and prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), administration of fresh frozen plasma (FFP) may be useful. It should not be instituted based on laboratory tests alone but should be considered in those with active bleeding and in those requiring an invasive procedure. There is no evidence that infusion of plasma stimulates the ongoing activation of coagulation. If transfusion of FFP is not possible in patients with bleeding because of fluid overload, consider using factor concentrates such as prothrombin complex concentrate, recognising that these will only partially correct the defect because they contain only selected factors, whereas in DIC there is a global deficiency of coagulation factors. Severe hypofibrinogenaemia (<1 g/l) that persists despite FFP replacement may be treated with fibrinogen concentrate or cryoprecipitate. In cases of DIC where thrombosis predominates, such as arterial or venous thromboembolism, severe purpura fulminans associated with acral ischemia or vascular skin infarction, therapeutic doses of heparin should be considered. In these patients where there is perceived to be a co-existing high risk of bleeding there may be benefits in using continuous infusion unfractionated heparin (UFH) due to its short half-life and reversibility. Weight adjusted doses (e.g. 10 mu/kg/h) may be used without the intention of prolonging the APTT ratio to 1.5-2.5 times the control. Monitoring the APTT in these cases may be complicated and clinical observation for signs of bleeding is important. In critically ill, non-bleeding patients with DIC, prophylaxis for venous thromboembolism with prophylactic doses of heparin or low molecular weight heparin is recommended. Consider treating patients with severe sepsis and DIC with recombinant human activated protein C (continuous infusion, 24 microg/kg/h for 4 d). Patients at high risk of bleeding should not be given recombinant human activated protein C. Current manufacturers guidance advises against using this product in patients with platelet counts of <30 x 10(9)/l. In the event of invasive procedures, administration of recombinant human activated protein C should be discontinued shortly before the intervention (elimination half-life approximately 20 min) and may be resumed a few hours later, dependent on the clinical situation. In the absence of further prospective evidence from randomised controlled trials confirming a beneficial effect of antithrombin concentrate on clinically relevant endpoints in patients with DIC and not receiving heparin, administration of antithrombin cannot be recommended. In general, patients with DIC should not be treated with antifibrinolytic agents. Patients with DIC that is characterised by a primary hyperfibrinolytic state and who present with severe bleeding could be treated with lysine analogues, such as tranexamic acid (e.g. 1 g every 8 h).
M Levi; C H Toh; J Thachil; H G Watson
Related Documents :
3696697 - Fibrinolytic behavior in long-standing branch retinal vein occlusion.
2909047 - Disseminated intravascular coagulation and the syndrome of hemolysis, elevated liver en...
11590527 - Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse t...
2496147 - Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator...
22786687 - Oral anticoagulation with edoxaban. focus on current phase iii clinical development.
23965297 - Relationship between seizure episode and sudden cardiac arrest in patients with epileps...
Publication Detail:
Type:  Journal Article; Practice Guideline     Date:  2009-02-12
Journal Detail:
Title:  British journal of haematology     Volume:  145     ISSN:  1365-2141     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-03-18     Completed Date:  2009-06-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  24-33     Citation Subset:  IM    
Department of Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / blood,  therapeutic use
Antifibrinolytic Agents / blood,  therapeutic use
Disseminated Intravascular Coagulation / blood,  diagnosis*,  therapy*
Hematologic Tests
Protein C / analysis,  therapeutic use
Recombinant Proteins / therapeutic use
Reg. No./Substance:
0/Anticoagulants; 0/Antifibrinolytic Agents; 0/Protein C; 0/Recombinant Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Post-thrombotic syndrome: prevalence, prognostication and need for progress.
Next Document:  The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-p...